{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Class (Stereo):
CHEMICAL (UNKNOWN)
Lidanserin is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist. In conscious spontaneously hypertensive rats intravenous injection of lidanserin caused dose-dependent blood pressure reductions. Lidanserin antagonises the excitatory effect of synaptically released 5-HT on central sympathoexcitatory neurons. Lidanserin is a potential antihypertensive compound which combines vasodilatatory effects due to selective alpha 1-receptor antagonistic action and platelet antiaggregatory, antivasospastic, and vasoprotective properties due to selective 5-HT2-receptor blockade.
Status:
Investigational
Source:
NCT03641313: Phase 2 Interventional Active, not recruiting Clinical Stage III Gastric Cancer AJCC v8
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
VX-970 (VE-822) is an ATR kinase inhibitor. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. Vertex Pharmaceuticals is developing VX 970 for the treatment of advanced solid tumours. Phase I/II development is underway in the US for small-cell lung cancer and in the UK for solid tumours. Phase II development of VX 970 as a combination therapy in urogenital cancer, ovarian, primary peritoneal and fallopian tube cancer indications is underway in the US.
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
INN:trimedoxime bromide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Trimedoxime is the only one of the major bispyridinium oxime with a propylene linked between the two pyridinium rings. Trimedoxime is an oxime cholinesterase (AChE) reactivator. It was shown that trimedoxime is a more potent reactivator of the DFP-inhibited AChE than pralidoxime and a better reactivator than obidoxime in the case of the tabun-inhibited enzyme. It can be used parenterally as an antidote adjunct to atropine in treating human or animal (organophosphate group) anticholinesterase pesticide toxicity. Trimedoxime was the first oxime that was efficient in the treatment of animals intoxicated with tabun. It could also protect animals poisoned with sarin or VX, but not the ones intoxicated with soman.
Status:
Investigational
Source:
NCT03570931: Phase 2/Phase 3 Interventional Active, not recruiting Infantile Neuroaxonal Dystrophy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02108756: Not Applicable Interventional Unknown status Bleeding Gastric Ulcer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:managlinat dialanetil [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Managlinat dialanetil (MB06322 or CS-917) is an inhibitor of fructose 1,6-bisphphosphatase.
Managlinat dialanetil is a bisamidate prodrug and its activation requires a two-step enzyme catalyzed reaction. Metabasis Therapeutics Inc in collaboration with Daiichi Sankyo Co Ltd was developing managlinat dialanetil for the potential treatment of type 2 diabetes.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nitracrine (Ledakrin, C-283) is an acridine derivative with potential cytostatic and antitumor activities. Nitracrine induces the unwinding of supercoiled DNA and binds to the DNA through intercalation, forming drug-DNA adducts and DNA interstrand crosslinks. This inhibits RNA synthesis, protein production, cell growth, DNA replication and cell proliferation; altogether, this may promote apoptosis. Since cancer cells have increased metabolism and proliferate at an increased rate, nitracrine may induce tumor cell apoptosis. The drug was used in clinics in Poland for the treatment of ovarian, colon, lung and mammary carcinomas. Some undesirable effects observed in clinics: e.g. nausea, vomiting and toxicity and mutagenicity of the
drug in S. typhimurium strongly limited the therapeutic use of nitracrine and promoted a search for more suitable analogues.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cloxypendyl is an antipsychotic drug, invented in the 1960s by the Deutsche Gold und Silber-Scheideanstalt vormals Roessler. The compound was 3.5 times more effective than chlorpromazine in the mouse catalepsy test. No clinical and commercial development was reported.
Status:
Investigational
Source:
NCT00728195: Phase 2 Interventional Completed Schizophrenia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
JNJ-37822681 is a novel, potent, specific, centrally active, dopamine D2 receptor antagonist, which was developed by Johnson & Johnson. This drug is in the phase II of clinical trial for the treatment of schizophrenia. JNJ-37822681 has optimal brain disposition and somnolence was the most frequently reported adverse effect.
